Citations

Clear

16280 citation(s) found for "Yu, David".

Design and Validation of the ADNI MR Protocol
Borowski, Bret, Felmlee, John, Thomas, David L. , Gunter, Jeffrey L. , Tosun, Duygu , Weiner, Michael S. W., Arani, Arvin , Reid, Robert I. , Buckner, Randy L. , Jung, Youngkyoo , Barkhof, Frederik , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093641 Get It

AbstractBackgroundPhase four of the Alzheimer’s Disease Neuroimaging Initiative (ADNI4) began in 2023. This time‐period corresponded to MRI vendors introducing product sequences with compressed sensing (CS), cross‐vendor adoption of arterial spin‐labelling (ASL) and multi‐band slice excitation, and hardware improvements (head‐coils, increased gradient amplitudes). These advances enabled the acquisition of new imaging measures and reduced scan times. The ADNI4 MRI protocol aims to maintain longitudinal consistency across two decades of data acquisition, while adopting new technologies. Here we describe the design and justification behind the ADNI4 protocol and list the target imaging biomarkers.MethodsThe ADNI4 MRI protocol includes 9 MRI sequences; i) T1‐weighted (T1w) MP‐RAGE, ii) a compressed sensing T1w MP‐RAGE, iii) 3D T2w FLAIR, iv) structural isotropic 3D T2w v) T2*‐weighted susceptibility imaging vi) multi‐post labelling delay (PLD) 3D ASL, vii) 2D multi‐band‐multiple‐shell diffusion (dMRI), viii) 2D multi‐band EPI BOLD ix) high resolution, limited field of view, imaging centered on the hippocampus. Table 1 gives a detailed summary of the key protocol parameters and lists some of the imaging biomarkers that can be obtained from each series.ResultsStructural imaging was kept consistent across imaging sites. Variations in vendor specific sequences, software upgrades, and hardware performance capabilities, resulted in variations in advanced imaging strategies. Table 2 highlights the advanced sequences introduced in ADNI4, which will gradually be implemented as the required upgrades and licenses are obtained at each site. The main advanced sequences that are new in ADNI4 from ADNI 3 are i) CS for T1w images, ii) pseudo‐continuous‐ASL (pCASL) being implemented on all 3 vendors (GE, Siemens, Philips), iii) multi‐PLD ASL, which allows for the generation of quantitative maps of cerebral blood‐flow (CBF) and arterial transit times (ATTs), iv) and isotropic 1mm3 resolution for 3D FLAIR. When ADNI4 began, product sequences that utilized artificial intelligence were not widely available and could not be adequately tested before the rollout of ADNI4.ConclusionsThe ADNI4 database will continue to help the neuroimaging community, not only extract valuable imaging biomarkers, but provide the data necessary to test the impact of advanced imaging strategies on diagnostic accuracy and disease sensitivity.
Developing a novel claim‐based algorithm to identify incident and prevalent dementia using Medicare claims of the Atherosclerosis Risk in Communities (ARIC) cohort
Pate, Virginia , Palta, Priya, Jonson‐Funk, Michelle , Wang, Tiansheng , Kim, Dae Hyun , Power, Melinda C. , Garden, Gwenn A. , Knopman, David S. , Stürmer, Til , Kucharska‐Newton, Anna

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S6 | Pages: No page available

10.1002/alz.089988 Get It

AbstractBackgroundPharmacoepidemiologic studies assessing drug effectiveness for Alzheimer’s disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real‐world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.MethodWe developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011‐2013; mean age 75.8 (SD 5.3) years) and 6 (2016‐2017; mean age 79.8 (SD 4.8) years) of the ARIC cohort with ≥ 1‐year continuous Medicare Part A & B enrollment prior to each visit. We evaluated algorithm performance (sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV)) against the gold standard of the ARIC dementia classification based on an extensive battery of neurocognitive tests administered at each visit. We compared performance of the new algorithm with that of three existing algorithms (Jain, Bynum, Lee) and their relaxed forms (4‐year window, dementia diagnosis plus a depression diagnosis or dementia evaluation procedure, ignoring code position) to identify incident (n = 90 at V6) and prevalent dementia (n = 190 at V5; n = 160 at V6).ResultThe newly developed primary algorithm requires presence of a dementia diagnosis code followed by another diagnosis code within 1 year (under condition that the following non‐specific ICD‐9 diagnostic codes, 290.40, 290.41, 290.11, 290.3, should appear no more than once), or a subsequent dementia treatment prescription within 90 days (requiring Medicare Part D enrollment ≥ 6 months). The PPV of the new algorithm in the identification of incident dementia was PPV of 72.7%, with a specificity of 99.1%, outperforming existing algorithms. Its sensitivity of 38.7% and NPV of 96.2% were comparable to those achieved by existing algorithms. Sensitivity analysis restricting to ICD‐10 diagnostic codes increased the PPV and attenuated its sensitivity by 6%. Similar comparative performance was observed in the identification of prevalent dementia.ConclusionA novel algorithm for identifying dementia from Medicare claims, developed using linked ARIC‐Medicare data, outperforms previous algorithms and stands as a valuable tool in the assessment of ADRD drugs from real‐world data.
Mayo Normative Studies: regression‐based normative data for remote self‐administration of the Stricker Learning Span, Symbols Test and Mayo Test Drive Screening Battery Composite for ages 33‐100 and validation in MCI and dementia
Frank, Ryan D. , Fan, Winnie Z. , Christianson, Teresa J., Stricker, John L. , Lucas, John A. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Stricker, Nikki H. , Boots, Elizabeth A. , Kremers, Walter K. , Machulda, Mary M. , Hassenstab, Jason , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S10 | Pages: No page available

10.1002/alz.094197 Get It

AbstractBackgroundFew normative data for computerized measures administered in unsupervised remote environments are available. We aimed to determine what variables to include in normative models for remote self‐administered assessments, develop normative data for measures administered through Mayo Test Drive (MTD, a multi‐device remote cognitive assessment platform) and evaluate application of norms.Method1240 adults ages 33‐100 (96% White) from the Mayo Clinic Study of Aging and Mayo Alzheimer’s Disease Research Center met normative sample inclusion criteria that included a concordant Cognitively Unimpaired (CU) diagnosis (3 independent raters all diagnosed CU) and CDR = 0 (see Table 1 for sample characteristics). Raw test scores were converted to normalized scaled scores. We derived regression‐based normative data that adjusted for age, age2, sex and education (base model); alternative models are also provided (age+age2+sex; age+ age2). We evaluated whether additional model terms beyond the base model were needed using an a priori cut‐off of 1% variance improvement in adjusted R2 over and above the base model. We examined rates of low test performance defined as performance below ‐1 SD in independent validation samples (n = 167 concordant CU, n = 64 mild cognitive impairment (MCI), n = 14 dementia). Rates are considered significantly different than expected when 95% confidence intervals (CIs) do not include the expected 14.7% base rate frequency.ResultNo additional potential model terms met our a priori cut‐off for inclusion beyond the base model (see Table 2), including other quadratic and cubic terms or interactions, device type, response input type, potential session interference, and national area deprivation index (ADI available in subset; N = 776). Application of norms showed expected rates of low test performance among CU participants (95% CI includes expected base rate) and significantly greater than expected rates of low test performance for all variables in MCI (e.g., 62.5% for composite) and dementia (e.g., 71.4% for composite; see Table 3).ConclusionTypical normative models appear appropriate for remote self‐administered measures and are sensitive to cognitive impairment. Device type and response input did not explain enough variance to warrant inclusion in normative models but are important for individual level interpretation. Future work will improve representation of individuals from under‐represented groups.
Amyloidosis and Heart Transplantation in a New Era
Lyle, Melissa , Wiedmeier-Nutor, Erin J, Lindpere, Vanda , Klanderman, Molly , Nativi-Nicolau, José , Leoni, Juan , Goswami, Rohan , Yip, Daniel , Patel, Parag C. , Sher, Taimur , Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Boilson, Barry A. , Kushwaha, Sudhir S. , Clavell, Alfredo L. , Steidley, D. Eric , Hardaway, Brian , Scott, Robert L. , LeMond, Lisa , Grogan, Martha, Rosenthal, Julie , Lyle, Melissa A , Farina, Juan Maria M, Wiedmeier-Nutor, Erin, Lindpere, Vanda , Nativi-Nicolau, Jose N, Leoni Moreno, Juan Carlos, Goswami, Rohan M , Rosenbaum, Andrew N , Steidley, David E, Hardaway, Brian W, Rosenthal, Julie L , AbouEzzeddine, Omar F , Farina, Juan M. , Leoni, Juan Carlos , Fonseca, Rafaël , Gertz, Morie A. , Dispenzieri, Angela , Grogan, Martha

Mayo Clinic

Clinical Transplantation | January 8, 2025 | Volume: 39 | Issue: 1 | Pages: No page available

10.1111/ctr.70070 | PMID 39775986 Get It

AbstractBackgroundThe prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.ObjectivesWe sought to describe survival post heart transplantation (HT) in amyloid compared with non‐amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.MethodsThis is a retrospective review of end‐stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020. Wait time was compared in the new versus old OPTN allocation era starting December 18, 2018 by Wilcoxon rank sum test. All‐cause mortality for those with and without CA was compared using Kaplan–Meier estimates with log rank analysis, censoring December 16, 2022.ResultsFifty‐five patients with CA underwent HT between 2007 and 2020, 8 light chain amyloidosis (AL) (14.5%), 28 hereditary transthyretin (ATTRv) (50.9%), 17 wildtype transthyretin (ATTRwt) (30.9%), and 2 hereditary apolipoprotein A1 (AApoA1) amyloidosis patients (3.6%). No significant difference in overall survival post‐transplant was seen in amyloid compared with non‐amyloid (p = 0.816). Median time to HT was shorter in the new system, 45 days (IQR 24, 78) versus 174 days (IQR 76.5, 483.5), p = 0.006. There was a decline in MOT in hereditary amyloidosis over time with the concomitant rise in disease‐targeted therapies.ConclusionsHT survival in CA patients was similar to non‐amyloid patients. The new allocation system benefits this cohort with shorter wait times. There is less MOT in hereditary amyloidosis with increased utilization of disease‐targeted therapy.
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial
Sands, Bruce E. , Rubin, David T. , Loftus, Edward V. , Wolf, Douglas C. , Colombel, Jean‐Frédéric , Regueiro, Miguel , Vermeire, Séverine , Afzali, Anita , Lawlor, Garrett, Ahmad, Harris A. , Wu, Hsiuanlin, Osterman, Mark T. , D’Haens, Geert , Colombel, J F. , Regueiro, Miguel , Afzali, Anita , Ahmad, Harris A , D'Haens, G , Loftus, Edward V , Rubin, David T , Sands, Bruce E , Vermeire, Séverine , Panaccione, Remo , Dignass, Axel , Lawlor, Garrett , Jain, Anjali

Mayo Clinic

American Journal of Gastroenterology | January 8, 2025 | Volume: 120 | Issue: 10 | Pages: 2339-2349

10.14309/ajg.0000000000003310 | PMID 39773524 Get It

INTRODUCTION: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during the True North (TN) study and its open-label extension (OLE) in biologic-exposed patients with UC. METHODS: TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period). Eligible patients could enter the OLE. Clinical outcomes were assessed at TN week (W) 10 and W52 and OLE W46 and W94. Symptomatic efficacy was evaluated through induction and in the OLE until W94. Safety was assessed. RESULTS: This analysis included 376 biologic-exposed patients. In the placebo-controlled cohort, more ozanimod-treated patients achieved clinical response than placebo at W10 regardless of the number or type of prior biologics; patients who used 1 vs ≥2 prior biologics achieved higher efficacy rates. Efficacy rates were higher at W52 than W10 and were similar across subgroups regardless of the number or type of prior biologics. Significantly greater proportions of ozanimod vs placebo patients achieved symptomatic response by W5 ( P = 0.0173) and symptomatic remission by W10 ( P = 0.0207). Among biologic-exposed TN W10 ozanimod nonresponders who entered the OLE, 61% achieved symptomatic response with an extra 10 weeks of ozanimod treatment. Ozanimod efficacy was durable for ∼3 years of continuous treatment in biologic-exposed W52 clinical responders who entered the OLE. No new safety signals were observed. DISCUSSION: Ozanimod was effective and safe in biologic-exposed patients with UC, but these patients may require more time to respond to treatment. Clinical trial registry website and trial numbers: ClinicalTrials.gov, numbers NCT02435992 and NCT02531126.
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Rabinovici, Gil D. , Knopman, David S., Donohoe, Kevin, Herscovitch, Peter, Kuo, Phillip H. , Lingler, Jennifer H. , Price, Julie C. , Salloway, Stephen P., Weber, Christopher J., Carrillo, María C. , Johnson, Keith A. , Rabinovici, Gil D , Arbizu, Javier , Benzinger, Tammie L.S. , Hansson, Oskar , Minoshima, Satoshi , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2025 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14338 | PMID 39776249 Get It

Abstract INTRODUCTION The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. METHODS The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand‐alone modalities. RESULTS For amyloid PET, seven scenarios were rated as appropriate, two as uncertain, and eight as rarely appropriate. For tau PET, five scenarios were rated as appropriate, six as uncertain, and six as rarely appropriate. DISCUSSION AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer's disease. Highlights A multidisciplinary workgroup convened by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging updated the appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. The goal of these updated AUC is to assist clinicians in identifying clinical scenarios in which amyloid or tau PET may be useful for guiding the diagnosis and management of patients who have, or are at risk for, cognitive decline These updated AUC are intended for dementia specialists who spend a significant proportion of their clinical effort caring for patients with cognitive complaints, as well as serve as a general reference for a broader audience interested in implementation of amyloid and tau PET in clinical practice.
Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward
Toro-Tobón, David , Ospina, Naykky Singh , Brito, Juan P. , Toro-Tobon, David , Singh Ospina, Naykky , Brito, Juan P

Mayo Clinic

Thyroid® | January 8, 2025 | Volume: 35 | Issue: 1 | Pages: 3-5

10.1089/thy.2024.0690 | PMID 39772719 Get It

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Bartlett, Nancy L. , Kim, Won Seog , Fleury, Isabelle , Laribi, Kamel , Bergua, Juan , Bouabdallah, Krimo , Forward, Nicholas, Bijou, Fontanet , MacDonald, David , Ghesquières, Hervé , Nowakowski, Grzegorz S. , Yasenchak, Christopher A. , Patterson, Monica, Ho, Linda , Rustia, Evelyn, Fanale, Michelle A. , Jie, Fei, Kim, Won Seog , Laribi, Kamel , Bergua, Juan Miguel , Bijou, Fontanet , MacDonald, David , Portell, Craig A , Nowakowski, Grzegorz S , Yasenchak, Christopher A , Bartlett, Nancy L , Hahn, Uwe, Laribi, Kamel , Portell, Craig A. , Kim, Jeong‐Ah

Mayo Clinic

Journal of Clinical Oncology | January 7, 2025 | Volume: 43 | Issue: 9 | Pages: 1061-1072

10.1200/jco-24-02242 | PMID 39772655 Get It

PURPOSE In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated the efficacy and safety of BV + Len + R versus placebo + Len + R in patients with R/R DLBCL. METHODS ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R/R DLBCL. Patients received BV or placebo once every 3 weeks, Len once daily, and R once every 3 weeks. The primary end point was overall survival (OS), and secondary end points included investigator-assessed progression-free survival (PFS) and objective response rate (ORR). A prespecified interim analysis was performed after 134 OS events, with two-sided P = .0232 as the efficacy boundary. RESULTS Patients (N = 230) were randomly assigned to receive BV + Len + R (n = 112) or placebo + Len + R (n = 118). Two patients in the placebo arm did not receive treatment. With a median follow-up of 16.4 months, the median OS was 13.8 months with BV + Len + R versus 8.5 months with placebo + Len + R (hazard ratio, 0.63 [95% CI, 0.45 to 0.89]; two-sided P = .009). The median PFS was 4.2 months with BV + Len + R versus 2.6 months with placebo + Len + R (hazard ratio, 0.53 [95% CI, 0.38 to 0.73]; two-sided P < .001). The ORR was 64% ([95% CI, 55 to 73]; two-sided P < .001) with BV + Len + R and 42% (95% CI, 33 to 51) with placebo + Len + R; complete response rates were 40% and 19%, respectively. Treatment-emergent adverse events (AEs) occurred in 97% of patients in both arms. In both arms, the most common treatment-emergent AEs were neutropenia, thrombocytopenia, diarrhea, and anemia. CONCLUSION BV + Len + R demonstrated a statistically significant survival benefit with a manageable safety profile in heavily pretreated patients with R/R DLBCL.